Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence

por Liseno, Jacob, Lager, Brittney, Miller, Catherine, Shankar, Sai L., Mendoza, Jason P., Lewin, James B.
Publicado 2021

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

por Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.
Publicado 2023

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews

por Gudesblatt, Mark, Roman, Cortnee, Singer, Barry A., Schmidt, Hollie, Thomas, Jessica, Shankar, Sai L., Lyons, Jennifer, Kapadia, Shivani
Publicado 2022

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

por Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.
Publicado 2022

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies

por Amezcua, Lilyana, Mao-Draayer, Yang, Vargas, Wendy S., Farber, Rebecca, Schaefer, Sara, Branco, Filipe, England, Sarah M., Belviso, Nicholas, Lewin, James B., Mendoza, Jason P., Shankar, Sai L.
Publicado 2023

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

por Wray, Sibyl, Then Bergh, Florian, Wundes, Annette, Arnold, Douglas L., Drulovic, Jelena, Jasinska, Elzbieta, Bowen, James D., Negroski, Donald, Naismith, Robert T., Hunter, Samuel F., Gudesblatt, Mark, Chen, Hailu, Lyons, Jennifer, Shankar, Sai L., Kapadia, Shivani, Mendoza, Jason P., Singer, Barry A.
Publicado 2022

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

por Singer, Barry A, Arnold, Douglas L, Drulovic, Jelena, Freedman, Mark S, Gold, Ralf, Gudesblatt, Mark, Jasinska, Elzbieta, LaGanke, Christopher C, Naismith, Robert T, Negroski, Donald, Oh, Jiwon, Hernandez Perez, Miguel Angel, Selmaj, Krzysztof, Then Bergh, Florian, Wundes, Annette, Ziemssen, Tjalf, Castro-Borrero, Wanda, Chen, Hailu, Levin, Seth, Scaramozza, Matthew, Shankar, Sai L, Wang, Ting, Wray, Sibyl
Publicado 2023